Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and/or an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: Disclosed herein are linker units comprising a center core, a plurality of linking arms, and optionally, a coupling arm. According to the embodiments of the present disclosure, the present linker units further comprises a targeting element and an effector element. Also disclosed herein are methods for treating various diseases using such linker units.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating osteoporosis using such molecular constructs are also disclosed.

Abstract: The present disclosure relates to anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, e.g., SVPHPRCHCGAGRA (SEQ ID NO: 4) and the uses thereof in treating IgE-mediated diseases.

Abstract: Disclosed herein is an anti-migis-??antibody specific for the migis-? of human m? chain that can bind to mIgA on B lymphocytes, cause the lysis of mIgA-expressing B lymphocytes, and decrease IgA production by IgA-secreting B lymphocytes. Disclosed further is a pharmaceutical composition comprising the anti-migis-? antibody and a pharmaceutically acceptable carrier. Disclosed further is a method for lysing mIgA-expressing B lymphocytes and reducing IgA production in a human subject in vivo by employing an antibody specific for the migis-? of human m? chain that can bind to mIgA on B lymphocytes, cause the lysis of mIgA-expressing B lymphocytes, and decrease IgA production by IgA-secreting B lymphocytes.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The transgenic non-human animals are constructed, in whose genome the coding sequences of one of the animal's endogenous immunoglobulin C? constant regions are replaced by human immunoglobulin C? constant region coding sequences. The transgenic animal is mouse, in whose genome the C?1 constant regions are replaced by the human immunoglobulin C? constant regions and the C? constant region is replaced by the human immunoglobulin C? constant region. The transgenic mouse yields humanized IgE-secreting B cells and antigen-specific humanized IgE after immunization. The transgenic animals are employed to prepare serum containing humanized IgE, antiserum containing antigen-specific humanized IgE, and monoclonal antigen-specific humanized IgE antibodies by hybridoma and other technologies.

Abstract: Antibodies binding to junction regions between the CH4 and C?mX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: Provided are transgenic non-human animals, in whose genome the coding sequence of one of the endogenous immunoglobulin C? constant regions is replaced by a human immunoglobulin C? constant regions coding sequence. One preferred transgenic animal is a mouse, in whose genome the C?1 constant regions are replaced by human immunoglobulin C? constant regions and the C? constant region is replaced by human immunoglobulin C? constant region. The transgenic mouse yields humanized IgE-secreting B cells and antigen-specific humanized IgE after immunization. Also provided are the applications of the transgenic animals for preparing serum which containing humanized IgE, antiserum which containing humanized IgE, and monoclonal antigen-specific humanized IgE antibodies by hybridoma or other technologies.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.